


Pathology Grand Rounds

Thursday, November 3rd 12:30-1:30 pm

Fitkin Amphitheater - LMP 1094 (also via Zoom)

Hosted by: Qin Yan, PhD



Qing Zhang, PhD Associate Professor of Pathology, UT Southwestern Medical Center

Identification of New Therapeutic Targets in Cancer Oxygen Sensing Signaling

Needs: The talk will focus on how we utilize genome-wide screening approaches to identify new therapeutic targets in cancers, including breast and kidney cancer. The presenter will also demonstrate on how we can therapeutically target these molecules in cancer.

Objectives: Understand how dysregulated oxygen sensing signaling pathway may contribute to the development of cancers; Understand on how we can utilize unbiased biochemical screening approach to identify novel therapeutic targets; Describe on how we can design therapeutic intervention strategies to mitigate the development of kidney cancer and breast cancer formation.

ZOOM LOGIN



Accreditation Statement: Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: Yale School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Financial Disclosures: Dr. Qing Zhang, PhD, Speaker to this activity is Consultant to Bristol Myers Squibb. Dr. Kurt A. Schalper, MD, PhD, faculty/planner for this educational activity, is Consultant to Fee-Clinica Alemana de Santigo, Takeda, EMD Serono(relationship has ended) Merck(relationship has ended), Parthenon(relationship has ended), Sensei Therapeutics(relationship has ended) Molecular Templates, Paid Consultant-AstraZeneca, Moderna(relationship has ended), Shattuck Labs, Agennus, Honoraria-Genmab(relationship has ended)|Speaker Bureau-PeerView(relationship has ended)|Grant or research support-Astra Zeneca, Surface Oncology, Eli Lily(relationship has ended), Merck, Boehringer Ingelheim, Takeda, Akoya, GlaxoSmithKline, Ribon Therapeutics-06/14/2022. Dr. Manju Prasad, Dr. Pallavi Gopal, Damaris Battaglia, Nicole Vallati, and Samara Diggs, faculty/planners for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.